Tarsus Pharmaceuticals (TARS) Stock: Buy, Sell, or Hold?
TARS - Tarsus Pharmaceuticals, Inc. Common Stock
$73.00
-2.46 (-3.26%)
▼
5d:
-3.55%
30d:
-11.79%
90d:
+8.87%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 03, 2026
29d
Get Alerted When TARS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: TARS shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: TARS shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: TARS is currently trading at $73.00, which is considered oversold relative to its 30-day fair value range of $73.07 to $82.30. From a valuation perspective, the stock is trading at a discount (Forward PE: -202.8) compared to its historical average (34.7). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TARS is in a strong uptrend. The price is currently testing key support at $72.94. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: TARS scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (13th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $99.50 (+36.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TARS is in a strong uptrend. The price is currently testing key support at $72.94. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: TARS scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (13th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $99.50 (+36.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$73.07 -
$82.30
Company Quality Score
51/100
(HOLD)
Options IV Signal
13th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
65.4%
Protect Your Profits
Holding TARS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 13th percentile)
- BEARISH: Weak technical setup (32/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.3%)
- BULLISH: Trading 36.3% below Wall St target ($99.50)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 51/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$73.07 -
$82.30
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$6.77
(9.3%)
Support & Resistance Levels
Support Level
$72.94
Resistance Level
$79.10
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-202.78
Wall Street Target
$99.50
(+36.3%)
Revenue Growth (YoY)
69.4%
Profit Margin
-7.7%
PE vs Historical
-202.8 vs 34.7
CHEAP
Share & Embed Analysis
Last updated: October 03, 2026 7:01 PM ET
Data refreshes hourly during market hours. Next update: 8:01 PM
Data refreshes hourly during market hours. Next update: 8:01 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TARS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 54 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 49 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$47 | 46 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$851 | 48 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$293 | 67 BUY |
Advanced TARS Option Strategies
Professional options setups generated by AI based on today's TARS price and gamma walls.
